Close Menu

commercialization agreement

Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.

Eurofins LifeCodexx will commercialize Osteolabs' osteoporosis test in Germany, while BioGen Medical will do the same in Turkey.

Eurobio Scientific will also develop new test kits for the T-COR 8, a real-time PCR thermocycler originally developed for the US Army.

The company received an initial $1.25 million and could receive another $6.5 million to develop and commercialize a machine-learning-based sepsis detection algorithm.

Under the agreement, Theradiag will promote, license, and distribute PredictImmune's PredictSure IBD test in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries. 

Under the deal, KSL will commercialize and facilitate orders of the PredictSURE IBD test throughout North America and will also process all samples through its laboratory, KSL Diagnostics.

The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.

Idylla molecular testing instruments will be placed at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.

Japan's Nichirei will register Biocartis' Idylla MDx oncology products with the Japanese Ministry of Health, Labor and Welfare.

While studies conducted by the company have found the test could significantly reduce unnecessary biopsies, sales have been modest to date.

Pages